IEMbase 0573: HNF1A-related MODY3 with hyperinsulinism
Scope
| Field | Value |
|---|---|
| IEMbase ID | 573 |
| Nosology | 24.1.06.01 |
| Gene | HNF1A |
| External IDs | OMIM:142410; ORPHA:552 |
| Generated mapping | UNMAPPED |
| Candidate DisMech targets | Congenital_Isolated_Hyperinsulinism.yaml#HNF4A/HNF1A-HI; Diabetes_Mellitus.yaml#HNF1A |
| Review date | 2026-07-07 |
IEMbase phenotype signal
IEMbase represents HNF1A-related MODY3. The record is autosomal dominant, idiopathic subtype, of unknown treatability, and has no treatment rows.
Biochemical rows include decreased free fatty acids during hypoglycemia, decreased ketones during hypoglycemia, low plasma glucose, and increased insulin during hypoglycemia. Characteristic rows include MODY3 diabetes, hyperinsulinism, and hypoketotic hypoglycemia.
DisMech phenotype coverage
Congenital_Isolated_Hyperinsulinism.yaml contains a combined HNF4A/HNF1A
transcription-factor hyperinsulinism subtype, describing hyperinsulinism in the
newborn period followed by MODY later in life. Diabetes_Mellitus.yaml includes
HNF1A as a causative monogenic diabetes gene and explicitly notes MODY3 context.
There is no standalone HNF1A/MODY3 disease entry.
Concordance and completeness
Judgement: generated false negative to local partial coverage; resolve the
hyperinsulinism aspect to
Congenital_Isolated_Hyperinsulinism.yaml#HNF4A/HNF1A-HI and the diabetes
aspect to Diabetes_Mellitus.yaml#HNF1A.
IEMbase agrees with local CHI context on HNF1A-related hyperinsulinism, hypoketotic hypoglycemia, low glucose, and suppressed ketone/free-fatty-acid signals. It agrees with the broad diabetes entry on HNF1A/MODY3 monogenic diabetes. The missing local content is a standalone HNF1A/MODY3 subtype entry that unifies both signals.
Curation actions
- Promote this record to the HNF4A/HNF1A transcription-factor hyperinsulinism
context in
Congenital_Isolated_Hyperinsulinism.yaml. - Retain
Diabetes_Mellitus.yaml#HNF1Aas monogenic-diabetes context. - Consider a future HNF1A/MODY3-specific entry or subtype if DisMech wants gene-specific MODY coverage outside broad diabetes.